Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26049755 | 0.87 | SLC6A1 (0.39) | CPN1CPB2GNAO1GNAI3GNAI1 | |
| SCHEMBL27912761 | 0.87 | SLC6A1 (0.39) | CPN1CPB2GNAO1GNAI3GNAI1 | |
| SCHEMBL5655242 | 0.83 | — | — | |
| SCHEMBL19173663 | 0.83 | CPN1 (0.38) | CPN1CPB2GNAO1GNAI3GNAI1 | |
| SCHEMBL1019292 | 0.80 | CPN1 (0.43) | CPN1CPB2GNAO1GNAI3GNAI1 | |
| SCHEMBL18922349 | 0.80 | CPN1 (0.52) | CPN1CPB2GNAO1GNAI3GNAI1 | |
| SCHEMBL27976955 | 0.79 | CPN1 (0.41) | CPN1CPB2GNAO1GNAI3GNAI1 | |
| SCHEMBL28881922 | 0.78 | CPN1 (0.38) | CPN1CPB2GNAO1GNAI3GNAI1 | |
| SCHEMBL11186422 | 0.78 | CPN1 (0.38) | CPN1CPB2GNAO1GNAI3GNAI1 | |
| SCHEMBL9383869 | 0.78 | GNAO1 (0.38) | CPN1CPB2GNAO1GNAI3GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2023212599-A2 | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF ESTROGEN RECEPTORS | ENDOTARGET INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20220388980-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | UNIV DREXEL (US) | 2022-12-08 | — | — | US | disclosed |
| US-11312700-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210002253-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2021-01-07 | — | — | US | disclosed |
| US-10858339-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | INTELLIKINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180134832-A1 | QUATERNARY PHOSPHONIUM COATED SURFACES AND METHODS OF MAKING THE SAME | ORTHOBOND INC (US) | 2018-05-17 | — | — | US | disclosed |
| EP-2809156-B1 | ALLOSTERIC MODULATORS OF 5-HYDROXYTRYPTAMINE 2C RECEPTOR (5-HT2CR) | UNIV TEXAS (US) | 2017-05-24 | — | — | EP | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
| WO-2009131129-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | 第一三共株式会社 (JP) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | PIK3CA, MTOR, PDPK1 | CPN1 2941/4885CPB2 3461/4885GNAO1 2345/4885 |
| US-20210002253-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | CPN1 3856/4885CPB2 4240/4885GNAO1 537/4885 |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | CPN1 3856/4885CPB2 4240/4885GNAO1 537/4885 |
| US-11312700-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | CPN1 3856/4885CPB2 4240/4885GNAO1 537/4885 |
| US-20220388980-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | RAD52, RECQL, RAD50 | CPN1 2415/4885CPB2 1633/4885GNAO1 2483/4885 |
| US-10858339-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | CPN1 3856/4885CPB2 4240/4885GNAO1 537/4885 |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | CPN1 3856/4885CPB2 4240/4885GNAO1 537/4885 |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | CDC25C, CCNC, CDC25B | CPN1 3238/4885CPB2 2832/4885GNAO1 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.